JRCT ID: jRCTs051190076
Registered date:29/11/2019
Neo-adjuvant combination chemotherapy of Tranilast in esophageal carcinoma
Basic Information
Recruitment status | Recruiting |
---|---|
Health condition(s) or Problem(s) studied | advanced esophageal squamous cell carcinoma |
Date of first enrollment | 14/11/2019 |
Target sample size | 59 |
Countries of recruitment | |
Study type | Interventional |
Intervention(s) | The additional use of tranilast to conventional neoadjuvant chemotherapy (5-FU/CDDP) for advanced esophageal squamous cell carcinoma patients |
Outcome(s)
Primary Outcome | Pathological therapeutic effect |
---|---|
Secondary Outcome | clinical safety, therapeutic response diagnosed by imaging examination, down staging, ontological outcomes, |
Key inclusion & exclusion criteria
Age minimum | >= 20age old |
---|---|
Age maximum | <= 74age old |
Gender | Both |
Include criteria | 1) Pathologically proven esophageal squamous cell carcinoma 2) Clinically diagnosed Stage II or Stage III esophageal squamous cell carcinoma patients in Japanese Classification of Esophageal Cancer, 11th edition 3) A case who was judged to be able to undergo radical esopagctomy under the general anesthesia 4) Age between 20 and 74 years old 5) A cases with ECOG Performance status 0,1 or 2 6) an essentially normal clinical laboratory profile (serum creatinine: <=1.2 mg /dl; (creatinine clearance or CCr) >=60 ml/minute; total serum bilirubin: <=1.2 mg /dl; aspartate aminotransaminase or AST and alanine aminotransaminase or ALT: no higher than twice upper limit of normal value defined in our institution; white blood cell count: >=4,000 /mm3; haemoglobin: >=10g /dl; platelet count: >=100,000 /mm3 7) A case that can take medicine. 8) Oral and written informed consent obtained before registration |
Exclude criteria | 1) A history of chemotherapy or radiotherapy 1 year before treatment begins 2) Tumor with active bleeding 3) A case with histories of acute myocardial infarction, severe angina, congested heart failure, cerebrovascular disease, or pulmonary thrombosis within 6 months before registration 4) A case with uncontrolled asthma 5) A history of laparotomy or trachotomy within 4 weeks before treatment begins 6) A case with allergy of tranilast 7) A female with a possibility of pregnancy, breastfeeding to infant, and desire to bear children 8) A case judged as inappropriate for the present clinical trial by the chief researcher 9) A case that take some similar drugs to tranilast 10) A case with transfusion within 14 days before registration 11) Current medication of warfarin |
Related Information
Primary Sponsor | Shiozaki Atsushi |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) |
Contact
Public contact | |
Name | Michihiro Kudou |
Address | 465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, JAPAN. Kyoto Japan 602-8566 |
Telephone | +81-752515527 |
posit@koto.kpu-m.ac.jp | |
Affiliation | University Hospital Kyoto prefectural University of Medicine |
Scientific contact | |
Name | Atsushi Shiozaki |
Address | 465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, JAPAN. Kyoto Japan 602-8566 |
Telephone | +81-752515527 |
shiozaki@koto.kpu-m.ac.jp | |
Affiliation | University Hospital Kyoto prefectural University of Medicine |